Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors or lymphoma. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response was 9 ...
The MarketWatch News Department was not involved in the creation of this content. Consensus-Built 'Fit-for-Purpose' Quality and Safety Standards for Community Oncology Programs OMAHA, NEBRASKA / ...
A substantial proportion of patients with autoimmune diseases experienced a new side effect called local immune effector cell–associated toxicity syndromes (LICATS) after receiving chimeric antigen ...
The FDA approved updated labeling for Carvykti (ciltacabtagene autoleucel, Janssen Biotech) to include a new boxed warning for immune effector cell-associated enterocolitis (IEC-EC). Carvykti is a ...
In patients with autoimmune hemolytic anemia (AIHA), the risk of relapse is high owing to persistent autoreactive B-cell activity. Multirefractory AIHA is a more advanced stage of disease that is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results